Real Chemistry buys Spurwing for first APAC healthcare hub
Real Chemistry’s Spurwing deal gives the healthcare communications group a Singapore base, but the real test is local senior counsel at scale.
Real Chemistry has acquired Spurwing Communications, making Singapore its first Asia Pacific strategic hub and giving the healthcare communications group a direct base in one of the region's more complex healthcare markets.
The deal brings Spurwing founder and CEO Emma Thompson into Real Chemistry as president, APAC growth, reporting to Kath Harrison, group president, international growth. It also gives Real Chemistry a local team with healthcare, agribusiness, food and nutrition communications experience, rather than a partnership-only model for APAC work.
Table of contents
Jump to each section:
- Why the deal matters
- What Spurwing adds in Singapore
- How this fits Real Chemistry model
- What clients should watch
Why the deal matters
For Real Chemistry, the acquisition is a geographic move, but it is also a capability signal. The company already describes itself as an end-to-end healthcare experience group spanning analytics, medical communications, advertising and integrated communications. Adding Spurwing gives that model a firmer operating base in Southeast Asia.
Harrison framed the logic around market access and healthcare innovation. "APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies," she said in the announcement.
That framing is sensible, but the practical test is narrower. Healthcare brands do not choose communications partners only because they have a hub on a map. They choose them because regulatory nuance, stakeholder access and local medical context can be handled without losing the discipline of a global account model.
What Spurwing adds in Singapore
Spurwing is a Singapore-based independent communications agency focused on healthcare, agribusiness, food and nutrition. Its own positioning emphasizes motivating stakeholder groups through relationships with industry stakeholders, journalists and thought leaders, which fits the kind of earned and advisory work healthcare brands often need in fragmented APAC markets.
The agency also gives Real Chemistry a local leadership story. Thompson will remain with the business, while Spurwing's existing team and client work are expected to continue as the integration unfolds. Earned First reported that Spurwing's team is approximately 12 people, a modest number in global network terms, but the value here is specialist market access rather than sheer headcount.
Spurwing had already moved toward AI-enabled advisory work before the deal. In January 2026, the agency announced a partnership with Sequencr AI for healthcare, agribusiness and food clients across APAC, covering areas such as AI search visibility, content generation and training. That gives the acquisition a clearer capability rationale than a simple office opening.
How this fits Real Chemistry model
Real Chemistry has been building a model that combines healthcare communications with data, analytics, media, medical affairs and AI-enabled delivery. In a March 2026 update, Real Chemistry said it generated US$560 million in 2025 revenue, up 14% from 2024, and that its international headcount had increased by 25% since 2023.
That puts the Spurwing acquisition in a broader expansion pattern. Real Chemistry is not trying to look like a traditional PR network with loosely connected country offices. It is trying to present itself as a healthcare commercialization partner that can combine communications, audience analytics, medical content and paid or owned engagement under one operating model.
The competitive field is not light. Inizio Evoke describes itself as a global health marketing, communications and transformation platform, while Omnicom Health presents itself as a multi-specialty healthcare communications network. Real Chemistry's difference is its healthcare-only focus plus a more explicit data and AI operating story, though clients will still judge the model by execution across markets.
What clients should watch
The useful signal for communications leaders is not that another global agency has planted an APAC flag. It is that specialist healthcare communications, AI search visibility and market-entry counsel are becoming more closely bundled.
For pharma, medtech and health innovation brands, the appeal is obvious. A regional hub can reduce coordination drag, improve local stakeholder judgment and make APAC work feel less like an extension of US or European playbooks.
The risk is equally familiar. Acquisitions can dilute the specialist culture that made a local agency valuable in the first place. Real Chemistry's next test is whether Spurwing keeps its senior counsel and market intimacy while gaining access to the larger group's analytics, medical communications and global client machinery.
For now, this is a notable APAC expansion rather than a market-shifting transaction. It gives Real Chemistry a stronger Singapore anchor, but the strategic payoff will depend on whether the combined firm can turn local expertise into repeatable regional work.
